The Gene and Virus Therapy Program (GVTP) is currently comprised of 19 members, both basic scientists and clinician investigators from 10 departments and divisions working interactively to develop novel genetically based approaches to the treatment of cancer. The goals of the Program are: 1) To enhance understanding of the biology of the viruses and cells that are used to create new gene delivery systems;2) To advance the technology base from which new gene and virus-based therapies can be created;and 3) To improve the outcomes of cancer treatment by developing new gene arid virus-based therapies and testing them in the clinic. These goals are supported by four major research themes: (I) vector development;(II) immuno-modulation;(III) preclinical and clinical pharmacology, and (IV) cell carriers. In addition to intensive intra-programmatic interactions, substantive inter-programmatic interactions, essential for the process of clinical translation, have been established between the GVTP and other MCCC Programs including the Hematologic Malignancies Program, the Women's Cancer Program, the Gastrointestinal Cancer Program, the Neuro-oncology Program and the Cancer Immunology &Immunotherapy Program. The leader. Dr. Evanthia Galanis, is an oncologist with considerable stature in the field of gene and virus therapy. The NIH funding base for the Program currently stands at $5,507,018 per annum in total costs (a 56% increase from last renewal), 68.3% of which represents NCI funding. Productivity of the Program during the current funding period has been significant, amounting to a total of 343 publications (as of 12/2012), in addition to the launching and/or completion of multiple Phase l/ll clinical trials in which recombinant viruses that were designed, constructed, preclinically tested, and manufactured at the Mayo Clinic have been administered to patients with various types of cancer. Additionally, there are several promising projects in the translational pipeline, including a recently approved IND to conduct first in-human clinical testing of a mesenchymal stem cell viral delivery platform;furthermore, a randomized phase II trial of the MV derivative MV-NIS versus oncologist chemotherapy of choice in recurrent ovarian cancer patients is in development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682934
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$143,793
Indirect Cost
$53,439
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97

Showing the most recent 10 out of 340 publications